ArticleBioMed research international2025
Mechanism of Curcumin in Inhibiting Proliferation of Head and Neck Squamous Cell Carcinoma: A Network Pharmacology and Cellular Experimental Study.
Article in BioMed research international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeted co-delivery of curcumin and TRAIL via engineered extracellular vesicles: a synergistic therapy against resistant cancers.Drug delivery and translational research · 2026Article
- Curcumin and Its Derivatives as Anticancer Agents in Head and Neck Cancer: Molecular Mechanisms and Preclinical Evidence.International journal of molecular sciences · 2026Review
- Curcumin and Cancer-Related Inflammation.Nutrients · 2026Review
- Melphalan and Curcumin Induce Apoptosis in Retinoblastoma Cells Associated with STAT3 Signaling Modulation.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in cancer therapy, head and neck squamous cell carcinoma (HNSCC) remains a challenging malignancy with limited treatment options, prompting this investigation into curcumin's antitumor mechanisms through integrated network pharmacology, molecular docking, and in vitro experiments. Our comprehensive analysis identified 34 potential targets, with AKT1, EGFR, and STAT3 emerging as core targets primarily involved in regulating proliferation, apoptosis, and migration via the EGFR/STAT3 pathway. Experimental validation demonstrated curcumin's dose-dependent inhibition of viability, invasion, and migration in FaDu and CAL 27 cells, while promoting apoptosis and downregulating EGFR/STAT3 expression at both mRNA and protein levels-effects that were synergistically enhanced when combined with AG490 inhibitor. RNA-seq analysis further confirmed STAT pathway suppression as a key anticancer mechanism, collectively establishing curcumin's therapeutic potential through EGFR/STAT3 axis modulation. Overall, these preliminary network pharmacology and in vitro experimental results suggest that curcumin is a potential therapeutic agent for HNSCC and is worthy of further study. This study provides a certain theoretical basis for future clinical exploration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.